Thus, SHIP1 potentially plays important roles in the pathophysiology associated with Alzheimer’s disease, and therefore, numerous small-molecule inhibitors of SHIP1 protein are currently being studied as possible immune-based therapies for AD. This evidence concerns the gene INPP5D and early-onset autosomal dominant Alzheimer disease.